Cord Blood PTT

From Ann Helen: Can you trust results of PTT and factor VIII in umbilical cord blood? It seems as if it is usual to draw umbilical cord blood from newborns when the mother is a known carrier of Hemophilia A. Can you trust a high APTT and a low factor VIII in such a sample? […]

Comments (2)

Bleeding Disorders

Jan 11 2021

george

New: CRYOcheck Hex LA

Congratulations to Precision BioLogic Inc. who today announce the release of their newly developed CRYOcheck HexLA® [click]. Following several years in development, CRYOcheck HexLA is FDA cleared, CE Marked, Health Canada authorized and ncluded on the Australian Register of Therapeutic Goods (ARTG). Thanks to PBI’d Elaine Benoit for the heads-up.

Thrombophilia

Platelet Clumping

Friend and Colleague Dennis Ernst, Center for Phlebotomy Education, shared this January 8, 2021 question with George: Hello Phlebotomy Today, We’ve come across a patient whose platelets clumped in EDTA and citrate tubes. We understand that ammonium oxalate may be used to provide an accurate platelet count. Do you know of a manufacturer of these […]

Specimen Management

Webinar: Von Willebrand Factor: Friend or Foe

Click here to register for our webinar, von Willebrand Factor, Friend or Foe. Von Willebrand Factor (VWF) is crucial to platelet adhesion and proper, effective coagulation. It also appears to be associated with inflammation and sepsis. Join us for a thought-provoking webinar entitled Von Willebrand Factor: Friend or Foe? as we explore the many faces […]

Bleeding Disorders

Jan, 2021 QQ: The Chromogenic Factor X Assay

Before 2010, several articles were published supporting the chromogenic factor X [CFX] assay [not to be confused with the chromogenic anti-factor Xa heparin assay] for monitoring warfarin therapy, especially in patients whose lupus anticoagulant [LAC} could falsely prolong the prothrombin time. Two of these articles are attached below. While the data published made it clear […]

Comments (1)

Anticoagulant Therapy

Jan 2 2021

george

December 2020 QQ: Emicixumab Responses

Here are the responses to our December, 2020 Quick Question: “What therapeutic does your center use for hemophilia A patients with inhibitors who bleed during emicizumab therapy?” There were only 6 voters Activated prothrombin complex concentrate [APCC]: 0 Recombinant activated factor VII [rFVIIa]: 4 Low-dose factor VIII: 1 High-dose factor VIII: 0 None, we see […]

Bleeding Disorders

CLS Journal Hemostasis Articles

A recent 2020 Clinical Laboratory Science Journal, publication of the American Society for Clinical Laboratory Science, offers the following hemostasis-related articles, purchasable for $5 each: Nardi MA. Emicizumab and the clinical laboratory. DOI: https://doi.org/10.29074/ascls.119.002204 Ketelson B. Molecular action of ADAMTS13 and transfusion therapies of thrombotic thrombocytopenia pupura. DOI: https://doi.org/10.29074/ascls.120.002287 Ketelson B. An overview of the […]

Bleeding Disorders

December 2020 Quick Question: Emicizumab

Our December, 2020 Quick Question addresses the uncommon incidence of breakthrough bleeds in hemophilia A patient who are being treated with emicizumab [HEMLIBRA], the immunotherapeutic that bypasses factor VIII. Treatment may become an issue in severe hemophilia in which patients develop inhibitors. See our November 29 post, Emicizumab Laboratory Assay Review [click] for some hints […]

Bleeding Disorders

November 2020 QQ: VWF Activity Assay Responses

Our November, 2020 Quick Question attracted 37 participants. Here is the stem: “Which VWF activity assay is preferred at your facility [check 10-31-20 post]?” The selections were… VWF:RCo: 58% [21] VWF:GP1bR: 3% [1] VWF:GP1gM: 14% [5] VWF:Ab: 3% [1] VWF:CBA: 22% [8]* The time-honored Ristocetin cofactor assay remains the most prevalent of VWF activity assays. […]

Bleeding Disorders

Emicizumab Laboratory Assay Review

Here is a comprehensive review of the 2017 hemophilia A therapeutic emicizumab [HEMLIBRA]. The author, Michael A. Nardi, MD, NYU Langone Health, details the effects of emicizumab on standard clot-based laboratory assays and the need for chromogenic substrate test methods. Click Nardi MA. Emicizumab and the clinical laboratory. Clin Lab Sci 2017; 30.DOI: https://doi.org/10.29074/ascls.119.002204.

Comments (0)

Bleeding Disorders

All Posts

Cord Blood PTT

New: CRYOcheck Hex LA

Platelet Clumping

Webinar: Von Willebrand Factor: Friend or Foe

Jan, 2021 QQ: The Chromogenic Factor X Assay

December 2020 QQ: Emicixumab Responses

CLS Journal Hemostasis Articles

December 2020 Quick Question: Emicizumab

November 2020 QQ: VWF Activity Assay Responses

Emicizumab Laboratory Assay Review

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question